Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Heterogeneity in refractory AML

Christopher Hourigan • 15 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia

Refractory acute myeloid leukemia (AML) has a poorly understood biology and prognosis. Here Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, discusses his group’s recent work in this area. Through transcriptomic analysis of treatment-naive AML, three chemorefractory patient groups with distinct expression profiles were identified. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Christopher Hourigan

1:39
How can MRD guide treatment of AML?
Christopher Hourigan • 4 Jun 2022
1:11
Current role of MRD in AML
Christopher Hourigan • 4 Jun 2022
1:09
Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT
Christopher Hourigan • 4 Jun 2022
2:50
Conditioning intensity and genomics: relapse after allogeneic transplant in MDS
Christopher Hourigan • 16 Jun 2020

Related Videos

1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
1:57
The FORUM trials: results of F1 and plans for F2
Christina Peters • 15 Apr 2024
5:28
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals